 "Aurobindo's US manufacturing facility gets inspectional observations")
The US Food and Drug Administration (US FDA) has issued a Form 483 with 9 observations to AuroLife Pharma LLC's oral solid manufacturing facility situated at Dayton, New Jersey, a wholly owned step-down subsidiary of Aurobindo Pharma Limited.
The US drug regulator inspected the plant from January 13 to February 12,2020 and issued a letter to the company to this effect while classifying the inspection as 'Official Action Indicated'.
Informing the development to the stock exchanges on Thursday, Aurobindo management said that this OAI classification may not have any material impact on the existing revenues, the supplies of its US business or pipeline products at this juncture.
The exclusive sales from this facility is around 2 per cent of the group's turnover, according to the filing. "The company will closely work with the regulator to comprehensively address the issues," Aurobindo said.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%